Today: 30 April 2026
PetroChina A-share stock price slips as LNG Canada stake-sale talk and oil swings set up Monday
17 January 2026
2 mins read

PetroChina A-share stock price slips as LNG Canada stake-sale talk and oil swings set up Monday

Shanghai, Jan 18, 2026, 04:19 CST — The market has closed.

  • PetroChina Class A (601857) ended at 9.80 yuan, slipping 1.7%, while the Shanghai Composite fell just 0.26%.
  • Reuters says Shell and Mitsubishi are looking into selling their stakes in LNG Canada, where PetroChina holds a 15% share.
  • Oil closed up Friday following a turbulent week, with experts pointing to geopolitics and Venezuelan supply disruptions as the upcoming drivers of price swings.

PetroChina Co., Ltd. Class A shares (601857) slipped 1.7% to 9.80 yuan on Friday, following a session range of 9.71 to 9.99 yuan. The Shanghai Composite wrapped up down 0.26% at 4,101.9.

China’s market is closed for the weekend, leaving PetroChina’s next move tied to two volatile benchmarks: crude and gas prices. The stock remains a key liquid proxy for energy risk in onshore trading, particularly when company updates run dry.

Late this week, a notable development emerged: Shell and Mitsubishi are considering selling their stakes in the C$40 billion ($28.8 billion) LNG Canada project, according to sources who spoke to Reuters. PetroChina owns a 15% share. Shell, in talks with Rothschild to gauge buyer interest, might sell up to 30% of the venture. At the same time, Mitsubishi has brought in RBC as it reviews its options, the sources added.

PetroChina investors aren’t debating if partners will cut back exposure — that’s a given. The real issue is how such moves affect the timing and cost of the next expansion. Changes in ownership stakes could reshape expectations for Phase 2 spending and governance, which in turn influences market valuations of PetroChina’s gas growth.

Oil prices edged higher Friday, with Brent closing at $64.13 a barrel, up 0.58%, and U.S. WTI finishing at $59.44, a 0.42% gain. Some investors were closing short positions ahead of the U.S. Martin Luther King Jr. holiday weekend. “Buying today seems to be people not wanting to be caught short over the long weekend,” said Phil Flynn, senior analyst at Price Futures Group. Reuters

Rising crude prices typically boost PetroChina’s upstream profits, yet refining margins can suffer if product prices don’t keep pace. This tug-of-war explains why the stock doesn’t always track oil closely, particularly when investors believe policy moves or demand shifts will dictate the next move rather than supply.

Leverage is under scrutiny back in China. Starting Jan. 19, Chinese stock exchanges will hike the minimum margin requirement for new loans from 80% to 100%. The China Securities Regulatory Commission greenlit the change as part of its promise to tighten oversight and clamp down on excessive speculation.

The risk scenario is clear. Should Iran-related tensions cool down more and the oil “risk premium” drop off, PetroChina might lose ground without any specific company news. On another front, if concerns about a global LNG glut grow stronger and LNG Canada’s expansion hits more hurdles, the offshore gas segment could lose its shine as a straightforward plus.

Traders will zero in on Monday’s reopening — Jan. 19 — when the higher margin requirement takes effect and PetroChina A-shares resume trading, with oil’s direction shaped by weekend headlines. Also in focus: any updates on LNG Canada stake talks hitting the tape.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
IonQ, Rigetti and QUBT move: what’s driving quantum computing stocks into next week
Previous Story

IonQ, Rigetti and QUBT move: what’s driving quantum computing stocks into next week

SMIC01 hits a record close in Thailand — what to watch next for the SMIC depositary receipt
Next Story

SMIC01 hits a record close in Thailand — what to watch next for the SMIC depositary receipt

Go toTop